CV Event Prediction, Risk Assessment in Type 2 Diabetes
The risk assessment method used in the SAVOR-53 TIMI trial provided a “practical, well-calibrated risk prediction tool.”
In the AWARD-7 trial, patients who received Trulicity 0.75mg or 1.5mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss vs patients who received traditional basal-bolus ...
Results showed the overall safety profile of linagliptin in study patients, including adults with kidney disease, was consistent with previous data.
Adjustment of glucose-lowering medications in patients who are at high-risk for severe hypoglycemia may be beneficial to prevent mild cognitive impairment.